Previous Close | 42.01 |
Open | 42.20 |
Bid | 43.82 x 200 |
Ask | 43.90 x 100 |
Day's Range | 41.30 - 43.92 |
52 Week Range | 31.86 - 45.00 |
Volume | |
Avg. Volume | 1,018,957 |
Market Cap | 5.58B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 18.19 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences:
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March 31, 2024, and provided an update on its recent corporate activities and outlook.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.